Physician profile
Amanda C Maxwell
NPI 1225352800
$3,755.97
in general payments reported to CMS, 2019-2025
25 companies · $937 in 2025
The $937 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $683 · 2023: $972 · 2024: $798 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.45 | 2021-2025 | |
| Pfizer INC. | $414.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $313.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $251.14 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $200.61 | 2021-2024 | Xarelto |
| Amgen INC. | $180.00 | 2022-2024 | Repatha |
| Merck Sharp & Dohme LLC | $176.26 | 2021-2025 | Verquvo, Recarbrio, Zerbaxa |
| Medtronic, INC. | $165.48 | 2025 | Symplicity G3 |
| Boston Scientific Corporation | $137.82 | 2024 | Watchman Flx |
| Mylan Specialty L.P. | $132.62 | 2022-2024 | Yupelri |
| Shionogi INC | $125.53 | 2023-2024 | Fetroja |
| Viatris Specialty LLC | $92.62 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $92.15 | 2023-2025 | Ultomiris, Soliris |
| Gilead Sciences, INC. | $91.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.98 | 2022-2025 | Andexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $72.21 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.41 | 2024-2025 | Lifevest |
| Smith+Nephew, INC. | $44.28 | 2023-2025 | Collagenase Santyl |
| Vertex Pharmaceuticals Incorporated | $44.04 | 2025 | |
| Mallinckrodt Hospital Products INC. | $41.71 | 2023-2024 | Terlivaz |
| Stryker Corporation | $40.24 | 2025 | Flowtriever |
| Inari Medical, INC. | $29.71 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $26.88 | 2025 | Uptravi |
| Chiesi USA, INC. | $19.76 | 2024 | Cleviprex |
| Melinta Therapeutics, LLC | $15.15 | 2025 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.